Through single cell sequencing of the tumor infiltrating lymphocytes of the clonal new antigen CD8, and transcriptional sequencing of bulk samples that are effective for immunotherapy, they finally determined that CCR5 and CXCL13 can be used as the internal immunotherapy sensitivity markers of T cells [49]. This evidence concerns the gene CCR5 and neoplasm.